Henry Schein (NASDAQ:HSIC – Get Rating) released quarterly earnings data on Tuesday. The company reported EPS of $1.30 for the quarter, beating the Zacks consensus estimate of $1.19 by $0.11, reports RTT News. Henry Schein had a net margin of 5.09% and a return on equity of 15.84%. The company posted revenue of $3.18 billion in the quarter, versus $3.12 billion expected by analysts. In the same period a year earlier, the company posted earnings per share of $1.24. The company’s revenue for the quarter increased by 8.7% compared to the same quarter last year.
HSIC opened at $80.45 on Tuesday. Henry Schein has a 1-year low of $70.25 and a 1-year high of $92.68. The company has a current ratio of 1.67, a quick ratio of 0.86 and a debt ratio of 0.20. The company has a market capitalization of $11.11 billion, a P/E ratio of 18.04, a price-to-earnings growth ratio of 1.41 and a beta of 0.75. The company has a fifty-day moving average price of $87.29 and a two-hundred-day moving average price of $80.39.
HSIC has been the subject of a number of research analyst reports. StockNews.com took over Henry Schein’s stock coverage in a Thursday, March 31 research note. They issued a “buy” rating on the stock. Morgan Stanley raised its price target on Henry Schein shares from $67.00 to $72.00 and gave the company an “underweight” rating in a Wednesday, Feb. 16 research note. Zacks Investment Research downgraded Henry Schein’s stock from a buy rating to a hold rating and set a target price of $95.00 for the company. in a research note from Tuesday, April 19. Barrington Research raised its price target on Henry Schein shares from $96.00 to $102.00 in a Wednesday, February 16 research note. Finally, Robert W. Baird raised his price target on Henry Schein shares from $98.00 to $103.00 in a Wednesday, February 16 research note. One financial analyst has assigned the stock a sell rating, another a hold rating and five a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $94.50.
In other Henry Schein news, Director Scott Philip Serota acquired 1,000 shares of Henry Schein in a trade dated Friday, March 4. The shares were purchased at an average cost of $85.87 per share, for a total transaction of $85,870.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available via this hyperlink. Additionally, Executive Vice President Mark E. Mlotek sold 24,075 shares of Henry Schein in a trade dated Thursday, Feb. 24. The shares were sold at an average price of $82.99, for a total transaction of $1,997,984.25. The disclosure of this sale can be found here. Insiders own 1.00% of the shares of the company.
Institutional investors have recently increased or reduced their stake in the stock. Barclays PLC increased its stake in Henry Schein shares by 14.4% in the fourth quarter. Barclays PLC now owns 249,861 shares in the company worth $19,374,000 after purchasing an additional 31,403 shares during the period. LPL Financial LLC increased its position in Henry Schein by 9.6% in the fourth quarter. LPL Financial LLC now owns 19,334 shares of the company worth $1,502,000 after purchasing an additional 1,701 shares in the last quarter. MML Investors Services LLC increased its position in Henry Schein by 4.9% in the fourth quarter. MML Investors Services LLC now owns 8,405 shares of the company worth $652,000 after buying 391 additional shares in the last quarter. HB Wealth Management LLC bought a new stock position in Henry Schein in the fourth quarter worth $225,000. Finally, Metropolitan Life Insurance Co NY increased its holdings of Henry Schein shares by 16.1% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 15,850 shares of the company worth $1,229,000 after acquiring an additional 2,200 shares during the period. Institutional investors and hedge funds own 94.30% of the company’s shares.
About Henry Schein (Get an evaluation)
Henry Schein, Inc provides healthcare products and services to dental practitioners and laboratories, medical practices, government, institutional healthcare clinics and other alternative care clinics worldwide. It operates through two segments, Healthcare Distribution, and Technology and Value Added Services.
Get news and reviews for Henry Schein Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Henry Schein and related companies with MarketBeat.com’s FREE daily email newsletter.